Mesa Laboratories, Inc. Logo

Mesa Laboratories, Inc.

MLAB

(1.8)
Stock Price

126,97 USD

-0.46% ROA

0.24% ROE

-736.3x PER

Market Cap.

528.389.540,00 USD

44.75% DER

0.65% Yield

0.45% NPM

Mesa Laboratories, Inc. Stock Analysis

Mesa Laboratories, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Mesa Laboratories, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (46%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

3 ROE

The stock's ROE falls within an average range (0.47%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (1.19%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's PBV ratio (1.25x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-7.650), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Mesa Laboratories, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Mesa Laboratories, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Mesa Laboratories, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Mesa Laboratories, Inc. Revenue
Year Revenue Growth
1988 1.000.000
1989 1.100.000 9.09%
1990 2.800.000 60.71%
1991 3.500.000 20%
1992 3.800.000 7.89%
1993 4.400.000 13.64%
1994 6.200.000 29.03%
1995 6.600.000 6.06%
1996 8.100.000 18.52%
1997 7.800.000 -3.85%
1998 7.900.000 1.27%
1999 8.100.000 2.47%
2000 8.655.331 6.42%
2001 9.099.963 4.89%
2002 9.043.844 -0.62%
2003 9.081.776 0.42%
2004 9.126.000 0.48%
2005 10.041.000 9.11%
2006 11.583.000 13.31%
2007 17.242.000 32.82%
2008 19.558.000 11.84%
2009 21.536.000 9.18%
2010 21.929.000 1.79%
2011 32.826.000 33.2%
2012 39.616.000 17.14%
2013 46.435.000 14.69%
2014 52.724.000 11.93%
2015 71.330.000 26.08%
2016 84.659.000 15.74%
2017 93.665.000 9.62%
2018 96.179.000 2.61%
2019 103.135.000 6.74%
2020 117.687.000 12.37%
2021 133.937.000 12.13%
2022 184.335.000 27.34%
2023 219.080.000 15.86%
2024 212.660.000 -3.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Mesa Laboratories, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 400.000 100%
1996 300.000 -33.33%
1997 300.000 0%
1998 300.000 0%
1999 200.000 -50%
2000 281.651 28.99%
2001 308.166 8.6%
2002 289.939 -6.29%
2003 259.966 -11.53%
2004 332.000 21.7%
2005 358.000 7.26%
2006 358.000 0%
2007 392.000 8.67%
2008 532.000 26.32%
2009 636.000 16.35%
2010 669.000 4.93%
2011 1.441.000 53.57%
2012 1.359.000 -6.03%
2013 2.011.000 32.42%
2014 2.320.000 13.32%
2015 3.294.000 29.57%
2016 3.972.000 17.07%
2017 4.157.000 4.45%
2018 3.539.000 -17.46%
2019 3.506.000 -0.94%
2020 6.355.000 44.83%
2021 10.388.000 38.82%
2022 15.767.000 34.12%
2023 20.490.000 23.05%
2024 19.972.000 -2.59%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Mesa Laboratories, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 2.300.000 100%
1997 2.100.000 -9.52%
1998 2.100.000 0%
1999 2.200.000 4.55%
2000 2.393.605 8.09%
2001 2.397.202 0.15%
2002 2.159.371 -11.01%
2003 2.238.095 3.52%
2004 2.117.000 -5.72%
2005 2.487.000 14.88%
2006 2.969.000 16.23%
2007 4.844.000 38.71%
2008 5.265.000 8%
2009 2.522.000 -108.76%
2010 2.541.000 0.75%
2011 4.576.000 44.47%
2012 5.416.000 15.51%
2013 9.117.000 40.59%
2014 11.464.000 20.47%
2015 17.058.000 32.79%
2016 23.618.000 27.78%
2017 22.814.000 -3.52%
2018 26.255.000 13.11%
2019 31.295.000 16.1%
2020 37.826.000 17.27%
2021 45.697.000 17.22%
2022 60.311.000 24.23%
2023 72.444.000 16.75%
2024 70.104.000 -3.34%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Mesa Laboratories, Inc. EBITDA
Year EBITDA Growth
1988 0
1989 100.000 100%
1990 600.000 83.33%
1991 1.100.000 45.45%
1992 1.200.000 8.33%
1993 1.300.000 7.69%
1994 1.800.000 27.78%
1995 2.200.000 18.18%
1996 2.600.000 15.38%
1997 2.600.000 0%
1998 2.800.000 7.14%
1999 3.000.000 6.67%
2000 3.177.837 5.6%
2001 3.925.212 19.04%
2002 3.057.187 -28.39%
2003 3.301.827 7.41%
2004 3.346.000 1.32%
2005 3.565.000 6.14%
2006 4.203.000 15.18%
2007 6.328.000 33.58%
2008 7.803.000 18.9%
2009 8.396.000 7.06%
2010 7.404.000 -13.4%
2011 11.821.000 37.37%
2012 15.538.000 23.92%
2013 13.104.000 -18.57%
2014 11.785.000 -11.19%
2015 15.864.000 25.71%
2016 16.323.000 2.81%
2017 16.313.000 -0.06%
2018 29.821.000 45.3%
2019 35.357.000 15.66%
2020 8.090.000 -337.05%
2021 12.358.000 34.54%
2022 4.702.000 -162.82%
2023 3.320.000 -41.63%
2024 30.704.000 89.19%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Mesa Laboratories, Inc. Gross Profit
Year Gross Profit Growth
1988 600.000
1989 700.000 14.29%
1990 1.600.000 56.25%
1991 2.300.000 30.43%
1992 2.600.000 11.54%
1993 3.000.000 13.33%
1994 4.100.000 26.83%
1995 4.400.000 6.82%
1996 5.300.000 16.98%
1997 5.100.000 -3.92%
1998 5.400.000 5.56%
1999 5.700.000 5.26%
2000 5.853.093 2.62%
2001 6.033.383 2.99%
2002 5.391.409 -11.91%
2003 5.684.537 5.16%
2004 5.698.000 0.24%
2005 6.320.000 9.84%
2006 7.437.000 15.02%
2007 10.895.000 31.74%
2008 12.858.000 15.27%
2009 13.817.000 6.94%
2010 13.194.000 -4.72%
2011 19.568.000 32.57%
2012 23.511.000 16.77%
2013 28.862.000 18.54%
2014 31.688.000 8.92%
2015 43.392.000 26.97%
2016 51.413.000 15.6%
2017 53.239.000 3.43%
2018 54.619.000 2.53%
2019 60.916.000 10.34%
2020 64.933.000 6.19%
2021 87.014.000 25.38%
2022 109.090.000 20.24%
2023 133.693.000 18.4%
2024 128.436.000 -4.09%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Mesa Laboratories, Inc. Net Profit
Year Net Profit Growth
1988 0
1989 100.000 100%
1990 400.000 75%
1991 900.000 55.56%
1992 900.000 0%
1993 900.000 0%
1994 1.000.000 10%
1995 1.200.000 16.67%
1996 1.600.000 25%
1997 1.700.000 5.88%
1998 2.100.000 19.05%
1999 2.100.000 0%
2000 2.106.619 0.31%
2001 1.832.268 -14.97%
2002 2.030.947 9.78%
2003 2.126.879 4.51%
2004 2.130.000 0.15%
2005 2.312.000 7.87%
2006 2.805.000 17.58%
2007 3.958.000 29.13%
2008 4.610.000 14.14%
2009 4.790.000 3.76%
2010 4.769.000 -0.44%
2011 6.183.000 22.87%
2012 7.919.000 21.92%
2013 8.450.000 6.28%
2014 9.000.000 6.11%
2015 9.583.000 6.08%
2016 11.169.000 14.2%
2017 11.183.000 0.13%
2018 -2.962.000 477.55%
2019 7.484.000 139.58%
2020 1.349.000 -454.78%
2021 3.274.000 58.8%
2022 1.871.000 -74.99%
2023 930.000 -101.18%
2024 -4.920.000 118.9%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Mesa Laboratories, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 1 0%
2000 1 0%
2001 1 0%
2002 1 0%
2003 1 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 100%
2008 1 0%
2009 2 0%
2010 1 0%
2011 2 0%
2012 2 50%
2013 3 0%
2014 3 0%
2015 3 0%
2016 3 33.33%
2017 3 0%
2018 -1 0%
2019 2 100%
2020 0 0%
2021 1 0%
2022 0 0%
2023 0 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Mesa Laboratories, Inc. Free Cashflow
Year Free Cashflow Growth
1990 300.000
1991 900.000 66.67%
1992 1.000.000 10%
1993 500.000 -100%
1994 700.000 28.57%
1995 -100.000 800%
1996 1.300.000 107.69%
1997 2.300.000 43.48%
1998 2.000.000 -15%
1999 2.700.000 25.93%
2000 -1.773.613 252.23%
2001 965.834 283.64%
2002 2.214.840 56.39%
2003 2.833.754 21.84%
2004 3.239.000 12.51%
2005 2.431.000 -33.24%
2006 2.191.000 -10.95%
2007 2.252.000 2.71%
2008 4.264.000 47.19%
2009 4.399.000 3.07%
2010 2.816.000 -56.21%
2011 6.228.000 54.78%
2012 11.806.000 47.25%
2013 10.494.000 -12.5%
2014 11.332.000 7.39%
2015 7.988.000 -41.86%
2016 9.174.000 12.93%
2017 -3.855.000 337.98%
2018 22.015.000 117.51%
2019 29.292.000 24.84%
2020 25.061.000 -16.88%
2021 35.081.000 28.56%
2022 34.791.000 -0.83%
2023 23.439.000 -48.43%
2024 9.142.000 -156.39%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Mesa Laboratories, Inc. Operating Cashflow
Year Operating Cashflow Growth
1990 300.000
1991 900.000 66.67%
1992 1.000.000 10%
1993 500.000 -100%
1994 700.000 28.57%
1995 900.000 22.22%
1996 1.700.000 47.06%
1997 2.400.000 29.17%
1998 2.200.000 -9.09%
1999 2.700.000 18.52%
2000 2.328.550 -15.95%
2001 1.045.887 -122.64%
2002 2.256.664 53.65%
2003 2.898.687 22.15%
2004 3.273.000 11.44%
2005 2.501.000 -30.87%
2006 2.306.000 -8.46%
2007 4.032.000 42.81%
2008 4.616.000 12.65%
2009 5.075.000 9.04%
2010 5.980.000 15.13%
2011 8.873.000 32.6%
2012 12.489.000 28.95%
2013 11.402.000 -9.53%
2014 12.373.000 7.85%
2015 10.816.000 -14.4%
2016 16.903.000 36.01%
2017 7.750.000 -118.1%
2018 24.814.000 68.77%
2019 30.554.000 18.79%
2020 26.559.000 -15.04%
2021 37.073.000 28.36%
2022 39.223.000 5.48%
2023 27.983.000 -40.17%
2024 9.776.000 -186.24%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Mesa Laboratories, Inc. Capital Expenditure
Year Capital Expenditure Growth
1990 0
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 1.000.000 100%
1996 400.000 -150%
1997 100.000 -300%
1998 200.000 50%
1999 0 0%
2000 4.102.163 100%
2001 80.053 -5024.31%
2002 41.824 -91.4%
2003 64.933 35.59%
2004 34.000 -90.98%
2005 70.000 51.43%
2006 115.000 39.13%
2007 1.780.000 93.54%
2008 352.000 -405.68%
2009 676.000 47.93%
2010 3.164.000 78.63%
2011 2.645.000 -19.62%
2012 683.000 -287.26%
2013 908.000 24.78%
2014 1.041.000 12.78%
2015 2.828.000 63.19%
2016 7.729.000 63.41%
2017 11.605.000 33.4%
2018 2.799.000 -314.61%
2019 1.262.000 -121.79%
2020 1.498.000 15.75%
2021 1.992.000 24.8%
2022 4.432.000 55.05%
2023 4.544.000 2.46%
2024 634.000 -616.72%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Mesa Laboratories, Inc. Equity
Year Equity Growth
1988 1.100.000
1989 1.200.000 8.33%
1990 1.700.000 29.41%
1991 2.600.000 34.62%
1992 3.500.000 25.71%
1993 4.400.000 20.45%
1994 5.400.000 18.52%
1995 6.300.000 14.29%
1996 8.000.000 21.25%
1997 9.600.000 16.67%
1998 11.200.000 14.29%
1999 11.900.000 5.88%
2000 12.599.464 5.55%
2001 12.932.958 2.58%
2002 13.894.274 6.92%
2003 14.486.523 4.09%
2004 15.384.000 5.83%
2005 15.379.000 -0.03%
2006 14.919.000 -3.08%
2007 20.723.000 28.01%
2008 23.739.000 12.7%
2009 27.602.000 14%
2010 31.197.000 11.52%
2011 36.417.000 14.33%
2012 43.915.000 17.07%
2013 52.753.000 16.75%
2014 64.333.000 18%
2015 73.479.000 12.45%
2016 84.678.000 13.23%
2017 97.821.000 13.44%
2018 99.361.000 1.55%
2019 111.311.000 10.74%
2020 220.013.000 49.41%
2021 406.227.000 45.84%
2022 393.801.000 -3.16%
2023 393.480.000 -0.08%
2024 387.759.000 -1.48%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Mesa Laboratories, Inc. Assets
Year Assets Growth
1988 1.200.000
1989 1.400.000 14.29%
1990 2.500.000 44%
1991 3.200.000 21.88%
1992 4.100.000 21.95%
1993 5.400.000 24.07%
1994 6.100.000 11.48%
1995 6.900.000 11.59%
1996 8.800.000 21.59%
1997 10.200.000 13.73%
1998 11.800.000 13.56%
1999 12.600.000 6.35%
2000 13.534.269 6.9%
2001 13.818.965 2.06%
2002 14.436.723 4.28%
2003 15.159.580 4.77%
2004 16.230.000 6.6%
2005 16.596.000 2.21%
2006 16.450.000 -0.89%
2007 22.354.000 26.41%
2008 25.533.000 12.45%
2009 29.614.000 13.78%
2010 33.639.000 11.97%
2011 50.984.000 34.02%
2012 50.696.000 -0.57%
2013 65.919.000 23.09%
2014 97.529.000 32.41%
2015 117.320.000 16.87%
2016 160.748.000 27.02%
2017 171.733.000 6.4%
2018 164.101.000 -4.65%
2019 156.767.000 -4.68%
2020 420.206.000 62.69%
2021 600.151.000 29.98%
2022 707.369.000 15.16%
2023 661.832.000 -6.88%
2024 637.188.000 -3.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Mesa Laboratories, Inc. Liabilities
Year Liabilities Growth
1988 100.000
1989 200.000 50%
1990 800.000 75%
1991 600.000 -33.33%
1992 600.000 0%
1993 1.000.000 40%
1994 700.000 -42.86%
1995 600.000 -16.67%
1996 800.000 25%
1997 600.000 -33.33%
1998 600.000 0%
1999 700.000 14.29%
2000 934.805 25.12%
2001 886.007 -5.51%
2002 542.449 -63.33%
2003 673.057 19.41%
2004 846.000 20.44%
2005 1.217.000 30.48%
2006 1.531.000 20.51%
2007 1.631.000 6.13%
2008 1.794.000 9.09%
2009 2.012.000 10.83%
2010 2.442.000 17.61%
2011 14.567.000 83.24%
2012 6.781.000 -114.82%
2013 13.166.000 48.5%
2014 33.196.000 60.34%
2015 43.841.000 24.28%
2016 76.070.000 42.37%
2017 73.912.000 -2.92%
2018 64.740.000 -14.17%
2019 45.456.000 -42.42%
2020 200.193.000 77.29%
2021 193.924.000 -3.23%
2022 313.568.000 38.16%
2023 268.352.000 -16.85%
2024 249.429.000 -7.59%

Mesa Laboratories, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
39.67
Net Income per Share
-0.13
Price to Earning Ratio
-736.3x
Price To Sales Ratio
2.47x
POCF Ratio
13.21
PFCF Ratio
14.53
Price to Book Ratio
1.36
EV to Sales
3.12
EV Over EBITDA
23.71
EV to Operating CashFlow
16.68
EV to FreeCashFlow
18.32
Earnings Yield
-0
FreeCashFlow Yield
0.07
Market Cap
0,53 Bil.
Enterprise Value
0,67 Bil.
Graham Number
14.68
Graham NetNet
-31.58

Income Statement Metrics

Net Income per Share
-0.13
Income Quality
-55.72
ROE
-0
Return On Assets
0
Return On Capital Employed
-0.01
Net Income per EBT
-1.6
EBT Per Ebit
0.06
Ebit per Revenue
-0.04
Effective Tax Rate
2.6

Margins

Sales, General, & Administrative to Revenue
0.33
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.61
Operating Profit Margin
-0.04
Pretax Profit Margin
-0
Net Profit Margin
0

Dividends

Dividend Yield
0.01
Dividend Yield %
0.65
Payout Ratio
-4.79
Dividend Per Share
0.64

Operating Metrics

Operating Cashflow per Share
7.42
Free CashFlow per Share
6.75
Capex to Operating CashFlow
-0.09
Capex to Revenue
-0.02
Capex to Depreciation
-0.11
Return on Invested Capital
-0.01
Return on Tangible Assets
-0
Days Sales Outstanding
62.07
Days Payables Outstanding
20.79
Days of Inventory on Hand
142.14
Receivables Turnover
5.88
Payables Turnover
17.55
Inventory Turnover
2.57
Capex per Share
-0.67

Balance Sheet

Cash per Share
6,61
Book Value per Share
71,98
Tangible Book Value per Share
-17.3
Shareholders Equity per Share
71.98
Interest Debt per Share
32.94
Debt to Equity
0.45
Debt to Assets
0.27
Net Debt to EBITDA
4.91
Current Ratio
2.96
Tangible Asset Value
-0,09 Bil.
Net Current Asset Value
-0,13 Bil.
Invested Capital
0.45
Working Capital
0,08 Bil.
Intangibles to Total Assets
0.75
Average Receivables
0,04 Bil.
Average Payables
0,01 Bil.
Average Inventory
34219000
Debt to Market Cap
0.33

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Mesa Laboratories, Inc. Dividends
Year Dividends Growth
2003 0
2004 0 0%
2005 1 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%

Mesa Laboratories, Inc. Profile

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

CEO
Mr. Gary M. Owens
Employee
698
Address
12100 West Sixth Avenue
Lakewood, 80228

Mesa Laboratories, Inc. Executives & BODs

Mesa Laboratories, Inc. Executives & BODs
# Name Age
1 Mr. Gary M. Owens
Chief Executive Officer, President & Director
70
2 Mr. John V. Sakys
Vice President, Chief Financial Officer & Chief Accounting Officer
70
3 Mr. Brian David Archbold
Senior Vice President of Continuous Improvement
70

Mesa Laboratories, Inc. Competitors